The long-term prognosis in terms of risk or predictors of developing hepatocellular carcinoma (HCC) among patients with sustained virological response (SVR) remains unclear. We conducted a retrospective cohort study using data from the Veterans Affairs VA hepatitis C virus (HCV) Clinical Case Registry in patients with positive HCV RNA between October 1999 and August 2009 and follow-up through December 2010. HCV treatment (interferon with or without ribavirin) and SVR (RNA test negative at least 12 weeks after the end of treatment) were determined. We used Cox's proportional hazards models to calculate hazard ratios (HRs) for potential predictors (demographic, virological, and clinical) associated with HCC development post-SVR. We identified 33,005 HCVinfected individuals who received treatment, of whom 10,817 achieved SVR. Among these patients,
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Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.28535/suppinfo. Table 1 . The annual risk of HCC following SVR in groups of patients stratified by the presence of cirrhosis diagnosis and or APRI at or before SVR date. High APRI is >2.0. Table 2 . Predictors of HCC after the first year of follow-up in Veterans with HCV who achieved an SVR. Results from Cox proportional hazards model while adjusting for the competing risk of death.
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Supplemental Figure 1
The cumulative incidence of hepatocellular carcinoma among patients with HCV who achieved SVR, stratified by age groups at the time of SVR. Gray's log-rank test p <.0001
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